CDKN2A and pancreatic neoplasm: CpG island methylator phenotype (CIMP)-high status [three/four or more methylated promoters among CACNA1G, CDKN2A, IGF2, and RUNX3] was observed in 12% (34/283) of the pancreatic cancer cases (Table 1).